Govt Cuts Price of 3 Anti-Cancer Drugs - Trastuzumab, Osimertinib, Durvalumab
By Rediff Money Desk, New Delhi Oct 29, 2024 16:25
India's government has asked manufacturers to reduce prices of three anti-cancer drugs - Trastuzumab, Osimertinib and Durvalumab - to reflect tax cuts. This follows a customs duty exemption and GST reduction.
New Delhi, Oct 29 (PTI) The government has asked the companies to reduce prices of three anti-cancer drugs to pass on the benefit of customs duty exemption and GST reduction to the consumers.
In line with the government's commitment to ensure the availability of drugs at affordable prices, the National Pharmaceutical Pricing Authority (NPPA) has issued an office memorandum directing the concerned manufacturers to reduce the MRP on three anti-cancer drugs, Trastuzumab, Osimertinib and Durvalumab.
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty, the Ministry of Chemicals and Fertilisers said in a statement.
The Department of Revenue, Ministry of Finance, issued a notification dated July 23, this year reducing the customs duty to nil on the three drugs.
"Accordingly, there should be a reduction in MRP of these drugs in the market and benefits of reduced taxes and duties should be passed on to the consumers," the ministry said.
Hence, NPPA has directed all the manufacturers of above-mentioned drugs to reduce their MRP, it added.
The manufacturers are required to issue a price list or supplementary price list to the dealers, state drugs controllers and the government indicating changes and to submit information regarding price changes to NPPA, the ministry said.
While presenting the Union Budget for 2024-25 in the Lok Sabha, Finance Minister Nirmala Sitharaman proposed to cut customs duties on Trastuzumab, Osimertinib and Durvalumab from 10 per cent to nil.
In line with the government's commitment to ensure the availability of drugs at affordable prices, the National Pharmaceutical Pricing Authority (NPPA) has issued an office memorandum directing the concerned manufacturers to reduce the MRP on three anti-cancer drugs, Trastuzumab, Osimertinib and Durvalumab.
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty, the Ministry of Chemicals and Fertilisers said in a statement.
The Department of Revenue, Ministry of Finance, issued a notification dated July 23, this year reducing the customs duty to nil on the three drugs.
"Accordingly, there should be a reduction in MRP of these drugs in the market and benefits of reduced taxes and duties should be passed on to the consumers," the ministry said.
Hence, NPPA has directed all the manufacturers of above-mentioned drugs to reduce their MRP, it added.
The manufacturers are required to issue a price list or supplementary price list to the dealers, state drugs controllers and the government indicating changes and to submit information regarding price changes to NPPA, the ministry said.
While presenting the Union Budget for 2024-25 in the Lok Sabha, Finance Minister Nirmala Sitharaman proposed to cut customs duties on Trastuzumab, Osimertinib and Durvalumab from 10 per cent to nil.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Thinkink Picturez
- 1.94 (+ 4.86)
- 69820171
- Rajnish Wellness
- 1.78 (+ 4.09)
- 54627483
- G G Engineering
- 1.80 (+ 1.12)
- 53423097
- GTL Infrastructure
- 2.32 ( 0.00)
- 34510899
- Vodafone Idea L
- 8.10 ( -0.25)
- 34418651
MORE NEWS
Vodafone Idea Raises Rs 1,980 Cr Through...
Vodafone Idea's board has approved the issuance of up to 175.53 crore shares on a...
Noida International Airport Passes Validation...
Noida International Airport has successfully completed its validation flight, a crucial...
Adani Group to Invest Rs 7.5 Lakh Cr in Rajasthan
Adani Group announces plans to invest Rs 7.5 lakh crore in Rajasthan across various...